Multicenter Selective Lymphadenectomy Trial (MSLT)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
John Wayne Cancer Institute
ClinicalTrials.gov Identifier:
NCT00275496
First received: January 10, 2006
Last updated: May 13, 2014
Last verified: May 2014

January 10, 2006
May 13, 2014
November 1993
June 2012   (final data collection date for primary outcome measure)
To determine whether wide excision of the primary with intraoperative lymphatic mapping (LM) followed by selective lymphadenectomy will effectively prolong overall survival compared to wide excision of the primary melanoma alone. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
To determine whether wide excision of the primary with intraoperative lymphatic mapping (LM) followed by selective lymphadenectomy will effectively prolong overall survival compared to wide excision of the primary melanoma alone.
Complete list of historical versions of study NCT00275496 on ClinicalTrials.gov Archive Site
Disease-free survival; Incidence, timing, and anatomic distribution of distant metastases; Morbidity of procedures; Significance of TA90 levels; Incidence of Sentinel Node Metastases (biopsy) vs clinical metastases (observation); Accuracy of LM [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
Disease-free survival; Incidence, timing, and anatomic distribution of distant metastases; Morbidity of procedures; Significance of TA90 levels; Sentinel node metastases in WEX arm; Incidence of nodal metastases; Accuracy of LM
Not Provided
Not Provided
 
Multicenter Selective Lymphadenectomy Trial (MSLT)
A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.

Subjects must be diagnosed with melanoma. All subjects receive Wide Excision (WEX) of their melanoma. If the melanoma meets study requirements, the subject is randomized to receive either (1) no further surgical procedures as part of the study or (2) a Selective Lymphadenectomy with the possibility of a Complete Lymphadenectomy. Subjects are then followed for 10 years.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Melanoma
  • Procedure: Sentinel Lymph Node Dissection
    Subject has wide excision and sentinel lymph node dissection for primary melanoma.
  • Procedure: Complete Lymph Node Dissection
    Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
  • Procedure: Wide Excision
    Subject has wide excision only for primary melanoma.
  • Active Comparator: WEX only
    Intervention: Procedure: Wide Excision
  • Active Comparator: WEX + SLND
    Intervention: Procedure: Sentinel Lymph Node Dissection
  • Active Comparator: WEX+SLND+CLND
    Intervention: Procedure: Complete Lymph Node Dissection

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2001
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The patient consents to be in the study.
  2. The patient must have invasive melanoma with: 1) Clark Level III and Breslow Thickness greater than or equal to 1.00 mm; or 2) Clark Level IV or V with any Breslow thickness. A confirmation of diagnosis and thickness must be made by the institutional pathologist.
  3. The primary cutaneous melanoma site must be on the head, neck, trunk, extremity, scalp, palm of the hand, sole of the foot, or subungual skin.
  4. The patient's biopsy must have been completed no more than 10 weeks before the initial visit to the clinic. (Surgery must be scheduled within three months of the biopsy.)
  5. The patient must be between 18 and 75 years old.
  6. The patient must have a life expectancy of at least 10 years from the time of diagnosis, excluding the diagnosis of melanoma.

Exclusion Criteria:

  1. The patient had a prior wide excision of the primary with a diameter of excision greater than or equal to 3.0 cm and the shortest margin from the tumor edge to the excision edge was measured by a pathologist to be greater than or equal to 1.5 cm; or the patient had an elliptical excision and a margin beyond the tumor edge was greater than or equal to 1.5 cm at the narrowest margin.
  2. The primary cutaneous melanoma involves the eye, ear, mucous membranes.
  3. The patient has clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases.
  4. The patient has a second primary invasive melanoma.
  5. The patient has had any type of solid tumor or hematologic malignancy during the past 5 years. Exceptions are if the patient has been treated for T1 lesions (e.g., squamous cell carcinoma of the skin, basal cell carcinoma or in situ carcinoma of the uterine cervix) during the past 5 years, but has not received treatment within the last 6 months.
  6. The patient has had prior skin grafts, tissue transfers or flaps, or lymph node dissections that may alter the lymphatic drainage pattern from a primary cutaneous melanoma to the adjacent regional lymph node basins.
  7. The patient has had previous chemotherapy, immunotherapy or radiation therapy.
  8. The patient has had an organ transplantation and is receiving immunosuppressive agents as a result of the transplantation.
  9. The patient has taken oral or parenteral steroids or immunosuppressive drugs within the last 6 months.
  10. The patient has any known primary or secondary immune deficiencies.
  11. The patient has another medical condition that will affect life expectancy.
  12. The patient is pregnant.
  13. Evidence that the patient cannot undergo selective lymph node dissection for any reason.
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00275496
MSLT-1, NIH P01 CA029605
Yes
John Wayne Cancer Institute
John Wayne Cancer Institute
National Institutes of Health (NIH)
Study Chair: Donald L Morton, MD John Wayne Cancer Institute
John Wayne Cancer Institute
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP